Amerise is a global research and innovation-driven Integrated pharmaceutical research company focusing on the NDA, 505(B)(2), and complex formulations.
Our team's core expertise is in developing injectables, ophthalmics, and oral dosage forms from research upto regulatory submission to deliver higher margins through a strong R&D setup having a team of experts.
Established in 2018 with an aim to contribute towards the well-being and improving the health of people around the globe through the provision of innovative and reliable pharmaceutical products and services.
Amerise Pharma offers proven expertise in providing regulatory-compliant & cost-effective Pharmaceutical product development for regulated markets.
To become a global recognized as domestic and internationally integrated pharmaceutical company through Innovation, Quality and Competence.
To be a globally admired, innovative, well recognized, best-in-class reputable pharmaceutical company. Amerise will seek to enhance its enterprise value in a sustainable manner with top quality management.
Agile and ambitious organization to fulfil customer requirements and market needs.
Motivated to achieve our aspirations with meticulous attention, planning and execution for commitments.
Rising with entrepreneur ethics as it is invisible assets of business’s existence
We work and operate in a respectful environment with both our clients and employees, this makes our work extra rewarding as we work to progress
Is our value of an honest and transparent organisation working together
Our team works and focuses on strategies which enable us to thrive and grow, importantly working as a supporting team enables us to deliver with quality
Working to processes and key measures ensures we all work efficiently and effectively, managing resources and saving on time where possible
Ready to use stable liquid herbal composition
Priority date : 30-Sep-20
Anti-vertigo compound and pharmaceutical compositions
Priority date : 20-Oct-20
Stable pharmaceutical composition of non-steroidal antiandrogens
Priority date : 15-Nov-21
Oral Pharmaceutical Composition
Priority date : 1-Sep-22